A phosphate-centric paradigm for pathophysiology and therapy of chronic kidney disease

Kidney International Supplements

Volumn 3, Issue 5, 2013, Pages 420-426

  Kuro O, Makoto ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Calciprotein particle (CPP); Fibroblast growth factor 23 (FGF23); Klotho; Phosphate restriction

Indexed keywords

CALCIPROTEIN PARTICLE; CALCIUM; FETUIN A; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; NANOPARTICLE; PHOSPHATE; UNCLASSIFIED DRUG;

AGING; BONE DEVELOPMENT; CELL DEATH; CHRONIC KIDNEY DISEASE; CYTOTOXICITY; DIET RESTRICTION; HUMAN; HYPERPHOSPHATEMIA; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY TUBULE DAMAGE; KIDNEY TUBULE EPITHELIUM; MINERAL METABOLISM; NONHUMAN; PATHOPHYSIOLOGY; PHOSPHATE EXCRETION; PHOSPHATE INTAKE; PHOSPHATE URINE LEVEL; PREMATURE AGING; REVIEW; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

EID: 84896702624     PISSN: 21571724     EISSN: 21571716     Source Type: Journal    
DOI: 10.1038/kisup.2013.88     Document Type: Review

References (84)

1. Hiza H, Bente L, Fungwe T. Nutrient content of the US food supply, 2005. U.S. Department of Agriculture, Center for Nutritional Policy and Promotion. Home Economics Research Report No. 58, 2008.
2. Uribarri J. Phosphorus additives in food and their effect in dialysis patients. Clin J Am Soc Nephrol 2009; 4: 1290-1292.
3. Schiavi SC, Kumar R. The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int 2004; 65: 1-14.
4. Kuro-o M. Phosphate and Klotho. Kidney Int 2011; 79: S20-S23.
5. Shimada T, Hasegawa H, Yamazaki Y et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19: 429-435.
6. White KE, Carn G, Lorenz-Depiereux B et al. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 2001; 60: 2079-2086.
7. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117: 4003-4008.
8. Kurosu H, Ogawa Y, Miyoshi M et al. Regulation of fibroblast growth factor-23 signaling by Klotho. J Biol Chem 2006; 281: 6120-6613.
9. Kuro-o M, Matsumura Y, Aizawa H et al. Mutation of the mouse Klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45-51.
10. Azuma M, Koyama D, Kikuchi J et al. Promoter methylation confers kidney-specific expression of the Klotho gene. FASEB J 2012; 26: 4264-4274.
11. Nagai T, Yamada K, Kim HC et al. Cognition impairment in the genetic model of aging Klotho gene mutant mice: a role of oxidative stress. FASEB J 2003; 17: 50-52.
12. Kamemori M, Ohyama Y, Kurabayashi M et al. Expression of Klotho protein in the inner ear. Hear Res 2002; 171: 103-110.
13. Toyama R, Fujimori T, Nabeshima Y et al. Impaired regulation of gonadotropins leads to the atrophy of the female reproductive system in Klotho-deficient mice. Endocrinology 2006; 147: 120-129.
14. Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408.
15. Suga T, Kurabayashi M, Sando Y et al. Disruption of the Klotho gene causes pulmonary emphysema in mice. Defect in maintenance of pulmonary integrity during postnatal life. Am J Respir Cell Mol Biol 2000; 22: 26-33.
16. Kawaguchi H, Manabe N, Miyaura C et al. Independent impairment of osteoblast and osteoclast differentiation in Klotho mouse exhibiting lowturnover osteopenia. J Clin Invest 1999; 104: 229-237.
17. Tsujikawa H, Kurotaki Y, Fujimori T et al. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 2003; 17: 2393-2403.
18. Shimada T, Kakitani M, Yamazaki Y et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004; 113: 561-568.
19. Farrow EG, Davis SI, Summers LJ et al. Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J Am Soc Nephrol 2009; 20: 955-960.
20. Olauson H, Lindberg K, Amin R et al. Targeted deletion of Klotho in kidney distal tubule disrupts mineral metabolism. J Am Soc Nephrol 2012; 23: 1641-1651.
21. Stubbs JR, Liu S, Tang W et al. Role of hyperphosphatemia and 1,25- dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol 2007; 18: 2116-2124.
22. Hesse M, Frohlich LF, Zeitz U et al. Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice. Matrix Biol 2007; 26: 75-84.
23. Razzaque MS, Sitara D, Taguchi T et al. Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. FASEB J 2006; 20: 720-722.
24. Ohnishi M, Nakatani T, Lanske B et al. Reversal of mineral ion homeostasis and soft-tissue calcification of Klotho knockout mice by deletion of vitamin D 1alpha-hydroxylase. Kidney Int 2009; 75: 1166-1172.
25. Ohnishi M, Razzaque MS. Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging. FASEB J 2010; 24: 3562-3571.
26. Beck L, Karaplis AC, Amizuka N et al. Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. Proc Natl Acad Sci USA 1998; 95: 5372-5377.
27. Ohnishi M, Nakatani T, Lanske B et al. In vivo genetic evidence for suppressing vascular and soft-tissue calcification through the reduction of serum phosphate levels, even in the presence of high serum calcium and 1,25-dihydroxyvitamin d levels. Circ Cardiovasc Genet 2009; 2: 583-590.
28. Di Marco GS, Hausberg M, Hillebrand U et al. Increased inorganic phosphate induces human endothelial cell apoptosis in vitro. Am J Physiol Renal Physiol 2008; 294: F1381-F1387.
29. Shuto E, Taketani Y, Tanaka R et al. Dietary phosphorus acutely impairs endothelial function. J Am Soc Nephrol 2009; 20: 1504-1512.
30. Six I, Maizel J, Barreto FC et al. Effects of phosphate on vascular function under normal conditions and influence of the uraemic state. Cardiovasc Res 2012; 96: 130-139.
31. Steitz SA, Speer MY, Curinga G et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001; 89: 1147-1154.
32. Jono S, McKee MD, Murry CE et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87: E10-E17.
33. Reynolds JL, Joannides AJ, Skepper JN et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004; 15: 2857-2867.
34. Sage AP, Lu J, Tintut Y et al. Hyperphosphatemia-induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro. Kidney Int 2011; 79: 414-422.
35. Villa-Bellosta R, Sorribas V. Phosphonoformic acid prevents vascular smooth muscle cell calcification by inhibiting calcium-phosphate deposition. Arterioscler Thromb Vasc Biol 2009; 29: 761-766.
36. Ewence AE, Bootman M, Roderick HL et al. Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization. Circ Res 2008; 103: e28-e34.
37. Nancollas GH, LoRe M, Perez L et al. Mineral phases of calcium phosphate. Anat Rec 1989; 224: 234-241.
38. Pak CYC, Eanes ED, Ruskin B. Spontaneous precipitation of brushite in urine: evidence that brushite is the nidus of renal stones originating as calcium phosphate. Proc Natl Acad Sci USA 1971; 68: 1456-1460.
39. Heiss A, Pipich V, Jahnen-Dechent W et al. Fetuin-A is a mineral carrier protein: small angle neutron scattering provides new insight on fetuin-a controlled calcification inhibition. Biophys J 2010; 99: 3986-3995.
40. Rochette CN, Rosenfeldt S, Heiss A et al. A shielding topology stabilizes the early stage protein-mineral complexes of fetuin-A and calcium phosphate: a time-resolved small-angle X-ray study. Chembiochem 2009; 10: 735-740.
41. Heiss A, Jahnen-Dechent W, Endo H et al. Structural dynamics of a colloidal protein-mineral complex bestowing on calcium phosphate a high solubility in biological fluids. Biointerphases 2007; 2: 16-20.
42. Heiss A, DuChesne A, Denecke B et al. Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem 2003; 278: 13333-13341.
43. Schafer C, Heiss A, Schwarz A et al. The serum protein alpha 2-Heremans- Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003; 112: 357-366.
44. Khoshniat S, Bourgine A, Julien M et al. Phosphate-dependent stimulation of MGP and OPN expression in osteoblasts via the ERK1/2 pathway is modulated by calcium. Bone 2010; 48: 894-902.
45. Herrmann M, Schäfer C, Heiss A et al. Clearance of fetuin-A-containing calciprotein particles is mediated by scavenger receptor-A. Circ Res 2012; 111: 575-584.
46. Hamano T, Matsui I, Mikami S et al. Fetuin-mineral complex reflects extraosseous calcification stress in CKD. J Am Soc Nephrol 2010; 21: 1998-2007.
47. Matsui I, Hamano T, Mikami S et al. Fully phosphorylated fetuin-A forms a mineral complex in the serum of rats with adenine-induced renal failure. Kidney Int 2009; 75: 915-928.
48. Smith ER, Ford ML, Tomlinson LA et al. Phosphorylated fetuin-Acontaining calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD. Nephrol Dial Transplant 2012; 27: 1957-1966.
49. Mackay EM, Oliver J. Renal damage following the ingestion of a diet containing an excess of inorganic phosphate. J ExpMed 1935; 61: 319-334.
50. Ori Y, Herman M, Tobar A et al. Acute phosphate nephropathy-an emerging threat. Am J Med Sci 2008; 336: 309-314.
51. Haut LL, Alfrey AC, Guggenheim S et al. Renal toxicity of phosphate in rats. Kidney Int 1980; 17: 722-731.
52. Bank N, Su WS, Aynedjian HS. A micropuncture study of renal phosphate transport in rats with chronic renal failure and secondary hyperparathyroidism. J Clin Invest 1978; 61: 884-894.
53. Lau K. Phosphate excess and progressive renal failure: the precipitationcalcification hypothesis. Kidney Int 1989; 36: 918-937.
54. Aihara K, Byer KJ, Khan SR. Calcium phosphate-induced renal epithelial injury and stone formation: involvement of reactive oxygen species. Kidney Int 2003; 64: 1283-1291.
55. Miller PD. The kidney and bisphosphonates. Bone 2011; 49: 77-81.
56. Francis MD, Russell RG, Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 1969; 165: 1264-1266.
57. Bertram JF, Douglas-Denton RN, Diouf B et al. Human nephron number: implications for health and disease. Pediatr Nephrol 2011.
58. Zhou XJ, Rakheja D, Yu X et al. The aging kidney. Kidney Int 2008; 74: 710-772.
59. Ibrahim HN, Foley R, Tan LT et al. Long-term consequences of kidney donation. N Engl J Med 2009; 360: 459-469.
60. Tan JC, Busque S, Workeneh B et al. Effects of aging on glomerular function and number in living kidney donors. Kidney Int 2010; 78: 686-692.
61. Young A, Hodsman AB, Boudville N et al. Bone and mineral metabolism and fibroblast growth factor 23 levels after kidney donation. Am J Kidney Dis 2011; 59: 761-769.
62. Robertson WG, Morgan DB. The distribution of urinary calcium excretions in normal persons and stone-formers. Clin Chim Acta 1972; 37: 503-508.
63. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205-2215.
64. Isakova T, Wahl P, Vargas GS et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79: 1370-1378.
65. Hasegawa H, Nagano N, Urakawa I et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 2010; 78: 975-980.
66. Vervloet MG, van Ittersum FJ, Büttler RM et al. Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Clin J Am Soc Nephrol 2010; 6: 383-389.
67. Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 2006; 91: 3144-3149.
68. Ito N, Fukumoto S, Takeuchi Y et al. Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J Bone Miner Metab 2007; 25: 419-422.
69. Gutierrez OM, Wolf M, Taylor EN. Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin J Am Soc Nephrol 2011; 6: 2871-2878.
70. Larsson T, Nisbeth U, Ljunggren O et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003; 64: 2272-2279.
71. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047.
72. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38.
73. Nelson RG, Tuttle KR. The new KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and CKD. Blood Purif 2007; 25: 112-114.
74. Gutierrez OM, Wolf M. Dietary phosphorus restriction in advanced chronic kidney disease: merits, challenges, and emerging strategies. Semin Dial 2010; 23: 401-406.
75. Moe SM, Zidehsarai MP, Chambers MA et al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 257-264.
76. Kajander EO, Ciftcioglu N. Nanobacteria: an alternative mechanism for pathogenic intra- and extracellular calcification and stone formation. Proc Natl Acad Sci USA 1998; 95: 8274-8279.
77. Kajander EO. Nanobacteria-propagating calcifying nanoparticles. Lett Appl Microbiol 2006; 42: 549-552.
78. Kajander EO, Ciftcioglu N, Miller-Hjelle MA et al. Nanobacteria: controversial pathogens in nephrolithiasis and polycystic kidney disease. Curr Opin Nephrol Hypertens 2001; 10: 445-452.
79. Young JD, Martel J, Young D et al. Characterization of granulations of calcium and apatite in serum as pleomorphic mineralo-protein complexes and as precursors of putative nanobacteria. PLoS One 2009; 4: e5421.
80. Young JD, Martel J, Young L et al. Putative nanobacteria represent physiological remnants and culture by-products of normal calcium homeostasis. PLoS One 2009; 4: e4417.
81. Wu CY, Martel J, Young D et al. Fetuin-A/albumin-mineral complexes resembling serum calcium granules and putative nanobacteria: demonstration of a dual inhibition-seeding concept. PLoS One 2009; 4: e8058.
82. Raoult D, Drancourt M, Azza S et al. Nanobacteria are mineralo fetuin complexes. PLoS Pathog 2008; 4: e41.
83. Togao O, Doi S, Kuro-o M et al. Assessment of renal fibrosis with diffusionweighted MR imaging: study with murine model of unilateral ureteral obstruction. Radiology 2010; 255: 772-780.
84. Doi S, Zou Y, Togao O et al. Klotho inhibits transforming growth factor-b1 (TGF-b1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem 2011; 286: 8655-8665.